Oda A, Druker B J, Smith M, Salzman E W
Department of Surgery, Beth Israel Hospital, Boston, Massachusetts 02115.
Am J Physiol. 1992 Mar;262(3 Pt 1):C701-7. doi: 10.1152/ajpcell.1992.262.3.C701.
Upon platelet activation, numerous proteins are known to be tyrosine phosphorylated. To investigate the mechanisms of the regulation of tyrosine phosphorylation and its physiological significance, the effects on tyrosine phosphorylation of agents that elevate the platelet level of the cyclic nucleotides cAMP and cGMP were examined in aspirin-treated gel-filtered platelets by Western blotting with a specific antiphosphotyrosine antibody. The effects of these agents on other aspects of platelet activation, i.e., aggregation, secretion, and elevation of the concentration of cytosolic ionized calcium ([Ca2+]i), were also examined in parallel experiments. Tyrosine phosphorylation in platelets activated by alpha-thrombin (1 nM) was inhibited by prostaglandin (PG) E1 (2 microM) or by sodium nitroprusside (100 microM). Elevation of [Ca2+]i, aggregation, and serotonin secretion was also strongly inhibited. On the other hand, a higher concentration of alpha-thrombin (10 nM) induced tyrosine phosphorylation of the same proteins, elevation of [Ca2+]i, platelet aggregation, and serotonin secretion, irrespective of pretreatment of platelets by either PGE1 or sodium nitroprusside. Inhibition by sodium nitroprusside of tyrosine phosphorylation induced by alpha-thrombin (1 nM) was accompanied by an increased concentration of cGMP. 8-BrcGMP (2 mM) also inhibited tyrosine phosphorylation and aggregation, although less than sodium nitroprusside. ADP (20 microM) induced platelet shape change and tyrosine phosphorylation of only a few proteins; these effects were also inhibited by either PGE1 or sodium nitroprusside. Thus tyrosine phosphorylation in platelets can be inhibited by elevation of either cAMP or cGMP, an effect that is overcome by a high concentration of thrombin, resulting in granule secretion and aggregation. Some of the proteins that are tyrosine phosphorylated may be important in the regulation of platelet functions.
在血小板活化时,已知有许多蛋白质会发生酪氨酸磷酸化。为了研究酪氨酸磷酸化的调节机制及其生理意义,通过用特异性抗磷酸酪氨酸抗体进行蛋白质印迹法,在阿司匹林处理过的凝胶过滤血小板中检测了提高环核苷酸cAMP和cGMP血小板水平的试剂对酪氨酸磷酸化的影响。在平行实验中还检测了这些试剂对血小板活化其他方面的影响,即聚集、分泌以及胞质游离钙离子([Ca2+]i)浓度升高。由α-凝血酶(1 nM)激活的血小板中的酪氨酸磷酸化受到前列腺素(PG)E1(2 μM)或硝普钠(100 μM)的抑制。[Ca2+]i升高、聚集和5-羟色胺分泌也受到强烈抑制。另一方面,较高浓度的α-凝血酶(10 nM)诱导相同蛋白质的酪氨酸磷酸化、[Ca2+]i升高、血小板聚集和5-羟色胺分泌,无论血小板是否预先用PGE1或硝普钠处理。硝普钠对α-凝血酶(1 nM)诱导的酪氨酸磷酸化的抑制伴随着cGMP浓度的增加。8-溴环鸟苷(2 mM)也抑制酪氨酸磷酸化和聚集,尽管作用小于硝普钠。ADP(20 μM)诱导血小板形态改变和仅少数蛋白质的酪氨酸磷酸化;这些作用也受到PGE1或硝普钠的抑制。因此,血小板中的酪氨酸磷酸化可通过升高cAMP或cGMP来抑制,而高浓度的凝血酶可克服这种作用,导致颗粒分泌和聚集。一些发生酪氨酸磷酸化的蛋白质可能在血小板功能调节中起重要作用。